+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Tissue Engineering Market Size, Share & Trends Analysis Report by Application (Cord Blood & Cell Banking, Cancer, GI & Gynecology, Dental, Orthopedics, Musculoskeletal, & Spine), by Region, and Segment Forecasts, 2020 - 2027

  • ID: 4538854
  • Report
  • February 2020
  • Region: Global
  • 140 pages
  • Grand View Research
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • ACell, Inc.
  • Allergan plc
  • Athersys, Inc.
  • Medtronic plc
  • ReproCell, Inc.
  • RTI Surgical, Inc.
  • MORE
The global tissue engineering market size is expected to reach USD 28.9 billion by 2027, expanding at a CAGR of 14.2%. Allogenic tissue transplant method efficiently addresses challenges and limitations regarding the implementation and availability of autologous transplants. Moreover, the development of specialized procedures including implant fixing and sterilization to transform allogeneic implants so for application as biostatic implants is expected to drive revenue generation in this market.

Rapid advancements and a strong pipeline of regenerative medicine are anticipated to provide effective solutions for chronic conditions. Several companies in growing markets are striving to capitalize on the untapped market potential with a strong focus on R&D. For instance, RepliCel is investing in multiple regenerative medicine products. As of 2019, its three products (RCH-01, RCS-01, RCT-01) were in the development phase and its dermal injector device (RCI-02) is under pre-commercialization production and testing phase.

The application of nanotechnology has played a critical role in the process of tissue engineering. Treating neurological diseases is a significant challenge as early diagnosis and treatment initiation is crucial. However, the advent of new 3D designed nanofibers has proved to be a ready alternative to aid the regeneration of damaged neurons. Such advances have propelled the growth of tissue engineering products.

Further key findings from the report suggest:
  • Cardiology and vascular application is one of the fastest-growing segments owing to an increasing incidence rate of heart failures worldwide
  • Since the past 20 years, cardiac cell therapy or cardiomyoplasty has been an important focal point of the majority of the studies aimed at heart disease management through regeneration
  • A rise in the number of children with congenital malformations such as single ventricle anomalies has led to the growing demand for heart transplantation
  • Tissue-engineered organs help address challenges related to the lack of suitable donor organ and potential side effects related to the transplantation, thereby driving the tissue engineering market growth
  • Orthopedic, musculoskeletal, and spine segment accounted for the major revenue share in 2019 and is anticipated to dominate the market for tissue engineering through 2027
  • The high share is attributable to frequent damage to musculoskeletal tissues or loss of tissue in disease or injury with limited repair probability
  • In addition, a rise in geriatric population, increasing sports-related injuries, and musculoskeletal disorders is also responsible for a high share of orthopedic, musculoskeletal, and spine segment
  • The lucrative opportunities proposed by emerging economies have drawn the attention of global leaders for investing in the Asia Pacific region. This is attributable to the fastest growth of the market for tissue engineering in the Asia Pacific region throughout the forecast period
  • Medtronic plc, Zimmer Biomet Holdings, Inc, Allergan plc, Athersys, Inc, ACell, Inc., Stryker Corporation, Integra LifeSciences Corporation, and Baxter International, Inc. are the key players operating in the market for tissue engineering
  • These participants are engaged in strategic alliances, deals, and development of novel products to sustain their market share.

Please note: This product will be delivered within 48 business hours after receipt of order.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • ACell, Inc.
  • Allergan plc
  • Athersys, Inc.
  • Medtronic plc
  • ReproCell, Inc.
  • RTI Surgical, Inc.
  • MORE
Chapter 1 Research Methodology
1.1 Information Procurement
1.1.1 Purchased database:
1.1.2 internal database
1.1.3 Secondary sources:
1.2 Third party perspective:
1.2.1 Primary research:
1.3 Sample size for the study on Tissue Engineering Market:
1.3.1 Primary Sources
1.3.2 Manufacturers -
1.3.3 Secondary Sources
1.4 Information or Data Analysis
1.5 Market Formulation & Validation
1.6 Objectives
1.6.1 Objective 1
1.6.2 Objective 2

Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights
2.4 Market Snapshot, 2019, (USD Million)

Chapter 3 Tissue Engineering Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.1.2 Related/ancillary market outlook
3.1.2.1 Stem cell market
3.1.2.2 3D cell culture market
3.2 Market Segmentation and Scope
3.3 Market Dynamics
3.3.1 Market driver analysis
3.3.1.1 Advancements in stem cell technology & tissue engineering
3.3.1.1.1 Nanotechnology potential
3.3.1.1.2 Technological advancements in biological implants
3.3.1.1.3 Introduction of novel platforms and technologies
3.3.1.2 Rise in number of clinical studies for regenerative medicine and tissue engineering
3.3.1.3 Increasing tissue engineering research funding
3.3.2 Market restraint analysis
3.3.2.1 High cost of product development
3.3.2.2 Ethical concerns related to stem cell research & tissue engineered product
3.3.2.3 Clinical issues pertaining to development & implementation of stem cell therapies
3.3.2.3.1 Manufacturing issues
3.3.2.3.2 Genetic instability
3.3.2.3.3 Condition of stem cell culture
3.3.2.3.4 Stem cell distribution after transplant
3.3.2.3.5 Immunological rejection
3.3.2.3.6 Challenges associated with allogenic mode of transplantation
3.4 Penetration & Growth Prospects Mapping, by Application, 2019
3.5 Tissue Engineering Market - PESTEL Analysis
3.6 Industry Analysis - Porter’s
3.7 Major Deals & Strategic Alliances Analysis
3.7.1 Collaboration & agreement
3.7.2 Joint venture

Chapter 4 Tissue Engineering Market: Application Estimates & Trend Analysis
4.1 Tissue Engineering Market: Application Movement Analysis
4.2 Cord Blood & Cell Banking
4.2.1 Cord Blood & Cell Banking Market, 2016 - 2027 (USD Million)
4.3 Cancer
4.3.1 Cancer Market, 2016 - 2027 (USD Million)
4.4 Gastrointestinal Disorders (GI) and Gynecology
4.4.1 GI & Gynecology Market, 2016 - 2027 (USD Million)
4.5 Dental
4.5.1 Dental Market, 2016 - 2027 (USD Million)
4.6 Skin & Integumentary
4.6.1 Skin & Integumentary Market, 2016 - 2027 (USD Million)
4.7 Urology
4.7.1 Urology Market, 2016 - 2027 (USD Million)
4.8 Orthopedics, Musculoskeletal, & Spine
4.8.1 Orthopedics, Musculoskeletal, & Spine Market, 2016 - 2027 (USD Million)
4.9 Neurology
4.9.1 Neurology Market, 2016 - 2027 (USD Million)
4.10 Cardiology & Vascular
4.10.1 Cardiology & Vascular Market, 2016 - 2027 (USD Million)
4.11 Others
4.11.1 Tissue Engineering Market for Other Applications, 2016 - 2027 (USD Million)

Chapter 5 Tissue Engineering Market: Regional Estimates & Trend Analysis, by Application
5.1 Tissue Engineering Market Share by Region, 2019 & 2027
5.2 North America
5.2.1 North America Tissue Engineering Market, 2016 - 2027 (USD Million)
5.2.2 U.S.
5.2.2.1 U.S. tissue engineering market, by application, 2016 - 2027 (USD Million)
5.2.3 Canada
5.2.3.1 Canada tissue engineering market, by application, 2016 - 2027 (USD Million)
5.3 Europe
5.3.1 Europe Tissue Engineering Market, by application, 2016 - 2027 (USD Million)
5.3.2 U.K.
5.3.2.1 U.K. tissue engineering market, by application, 2016 - 2027 (USD Million)
5.3.3 Germany
5.3.3.1 Germany tissue engineering market, by application, 2016 - 2027 (USD Million)
5.3.4 France
5.3.4.1 France tissue engineering market, by application, 2016 - 2027 (USD Million)
5.4 Asia Pacific
5.4.1 Asia Pacific Tissue Engineering Market, 2016 - 2027 (USD Million)
5.4.2 Japan
5.4.2.1 Japan tissue engineering market, by application, 2016 - 2027 (USD Million)
5.4.3 China
5.4.3.1 China tissue engineering market, by application, 2016 - 2027 (USD Million)
5.4.4 India
5.4.4.1 India tissue engineering market, by application, 2016 - 2027 (USD Million)
5.5 Latin America
5.5.1 Latin America Tissue Engineering Market, 2016 - 2027 (USD Million)
5.5.2 Brazil
5.5.2.1 Brazil Tissue engineering market, by application, 2016 - 2027 (USD Million)
5.5.3 Mexico
5.5.3.1 Mexico tissue engineering market, by application, 2016 - 2027 (USD Million)
5.6 MEA
5.6.1 MEA Tissue Engineering Market, 2016 - 2027 (USD Million)
5.6.2 South Africa
5.6.2.1 South Africa tissue engineering market, by application, 2016 - 2027 (USD Million)

Chapter 6 Competitive Landscape
6.1 Company Categorization
6.2 Tissue Engineering Market Position Analysis (Based on Products, Market Presence, Service Portfolio, Regional Presence)
6.3 List of key players (public and private) operating in the tissue engineering market
6.4 Strategy Framework
6.5 Company Profiles
6.5.1 Medtronic plc
6.5.1.1 Company overview
6.5.1.2 Financial performance
6.5.1.3 Product benchmarking
6.5.1.4 Strategic initiatives
6.5.2 Zimmer Biomet Holdings, Inc.
6.5.2.1 Company overview
6.5.2.2 Financial performance
6.5.2.3 Product benchmarking
6.5.2.4 Strategic initiatives
6.5.3 Allergan plc
6.5.3.1 Acelity L.P. Inc. (LifeCell)
6.5.3.2 Company overview
6.5.3.3 Financial performance
6.5.3.3.1 Financial performance: Acility
6.5.3.4 Product benchmarking
6.5.3.5 Strategic initiatives
6.5.4 ACell, Inc.
6.5.4.1 Company overview
6.5.4.2 Product benchmarking
6.5.4.3 Strategic initiatives
6.5.5 Athersys, Inc.
6.5.5.1 Company overview
6.5.5.2 Financial performance
6.5.5.3 Product benchmarking
6.5.5.4 Strategic initiatives
6.5.6 Organogenesis Holdings Inc.
6.5.6.1 Company overview
6.5.6.2 Financial performance
6.5.6.3 Product Benchmarking
6.5.6.4 Strategic initiatives
6.5.7 Stryker Corporation
6.5.7.1 Company overview
6.5.7.2 Financial performance
6.5.7.3 Product benchmarking
6.5.7.4 Strategic initiatives
6.5.8 Tissue Regenix Group plc
6.5.8.1 Company overview
6.5.8.2 Financial performance
6.5.8.3 Product benchmarking
6.5.8.4 Strategic initiatives
6.5.9 RTI Surgical, Inc.
6.5.9.1 Company overview
6.5.9.2 Financial performance
6.5.9.3 Product benchmarking
6.5.9.4 Strategic initiatives
6.5.10 ReproCell, Inc.
6.5.10.1 Company overview
6.5.10.2 Product benchmarking
6.5.10.3 Strategic initiatives
6.5.11 Integra LifeSciences Corporation
6.5.11.1 Company overview
6.5.11.2 Financial performance
6.5.11.3 Product benchmarking
6.5.11.4 Strategic initiatives
6.5.12 Baxter International, Inc.
6.5.12.1 Company overview
6.5.12.1.1 Synovis Micro Companies Alliance, Inc.
6.5.12.2 Financial performance
6.5.12.3 Product benchmarking
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Medtronic plc
  • Zimmer Biomet Holdings, Inc.
  • Allergan plc
  • Acelity L.P. Inc. (LifeCell)
  • ACell, Inc.
  • Athersys, Inc.
  • Organogenesis Holdings Inc.
  • Stryker Corporation
  • Tissue Regenix Group plc
  • RTI Surgical, Inc.
  • ReproCell, Inc.
  • Integra LifeSciences Corporation
  • Baxter International, Inc.
  • Synovis Micro Companies Alliance, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll